Back to Search
Start Over
1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study.
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS1026-S1027. 2p. - Publication Year :
- 2022
- Subjects :
- *NON-small-cell lung carcinoma
*DOCETAXEL
*SUBGROUP analysis (Experimental design)
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159077942
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.1157